KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 74 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,818,705 | -24.0% | 8,819,929 | +1.6% | 0.00% | – |
| Q2 2023 | $15,544,589 | -46.7% | 8,684,128 | +15.7% | 0.00% | -100.0% |
| Q1 2023 | $29,189,922 | +65.2% | 7,503,836 | +44.4% | 0.00% | – |
| Q4 2022 | $17,671,507 | -32.8% | 5,197,502 | +8.0% | 0.00% | -100.0% |
| Q3 2022 | $26,282,000 | +38.0% | 4,813,399 | +14.0% | 0.00% | 0.0% |
| Q2 2022 | $19,041,000 | -34.8% | 4,221,980 | +6.6% | 0.00% | 0.0% |
| Q1 2022 | $29,190,000 | +35.2% | 3,960,708 | +17.9% | 0.00% | – |
| Q4 2021 | $21,597,000 | +1.9% | 3,358,807 | -7.8% | 0.00% | -100.0% |
| Q3 2021 | $21,201,000 | -43.1% | 3,642,699 | +0.8% | 0.00% | 0.0% |
| Q2 2021 | $37,290,000 | -0.3% | 3,613,336 | +1.6% | 0.00% | 0.0% |
| Q1 2021 | $37,414,000 | -30.6% | 3,556,453 | +2.2% | 0.00% | -50.0% |
| Q4 2020 | $53,877,000 | +7.1% | 3,480,399 | +1.1% | 0.00% | 0.0% |
| Q3 2020 | $50,284,000 | -25.5% | 3,444,065 | -3.4% | 0.00% | 0.0% |
| Q2 2020 | $67,501,000 | +8.2% | 3,564,005 | +9.7% | 0.00% | -33.3% |
| Q1 2020 | $62,403,000 | +17.7% | 3,248,459 | +17.4% | 0.00% | +50.0% |
| Q4 2019 | $53,023,000 | +100.8% | 2,765,891 | +0.8% | 0.00% | +100.0% |
| Q3 2019 | $26,402,000 | +47.7% | 2,744,561 | -8.0% | 0.00% | 0.0% |
| Q2 2019 | $17,874,000 | +17.1% | 2,983,862 | +14.1% | 0.00% | 0.0% |
| Q1 2019 | $15,267,000 | -5.8% | 2,614,272 | +51.2% | 0.00% | 0.0% |
| Q4 2018 | $16,199,000 | -60.6% | 1,728,887 | -28.3% | 0.00% | -50.0% |
| Q3 2018 | $41,092,000 | -3.0% | 2,412,882 | -3.2% | 0.00% | 0.0% |
| Q2 2018 | $42,360,000 | +63.0% | 2,493,214 | +28.8% | 0.00% | +100.0% |
| Q1 2018 | $25,981,000 | +50.2% | 1,936,043 | +7.5% | 0.00% | 0.0% |
| Q4 2017 | $17,293,000 | -11.0% | 1,801,391 | +1.8% | 0.00% | 0.0% |
| Q3 2017 | $19,431,000 | +32.4% | 1,769,666 | +9.1% | 0.00% | 0.0% |
| Q2 2017 | $14,675,000 | -7.6% | 1,621,420 | +31.1% | 0.00% | 0.0% |
| Q1 2017 | $15,880,000 | +49.9% | 1,236,762 | +9.8% | 0.00% | 0.0% |
| Q4 2016 | $10,591,000 | +23.5% | 1,126,669 | +27.8% | 0.00% | 0.0% |
| Q3 2016 | $8,578,000 | +56.6% | 881,605 | +8.0% | 0.00% | – |
| Q2 2016 | $5,478,000 | -10.8% | 816,444 | +18.5% | 0.00% | – |
| Q1 2016 | $6,144,000 | -33.9% | 688,730 | -1.9% | 0.00% | -100.0% |
| Q4 2015 | $9,302,000 | -36.7% | 702,058 | -49.7% | 0.00% | 0.0% |
| Q3 2015 | $14,706,000 | -22.9% | 1,396,522 | +99.3% | 0.00% | 0.0% |
| Q2 2015 | $19,067,000 | +10.8% | 700,716 | +24.7% | 0.00% | 0.0% |
| Q1 2015 | $17,204,000 | +10.6% | 562,049 | +35.2% | 0.00% | 0.0% |
| Q4 2014 | $15,559,000 | +16.8% | 415,689 | +9.0% | 0.00% | 0.0% |
| Q3 2014 | $13,319,000 | -3.5% | 381,197 | +28.6% | 0.00% | 0.0% |
| Q2 2014 | $13,798,000 | +211.1% | 296,407 | +106.4% | 0.00% | – |
| Q1 2014 | $4,435,000 | +147.1% | 143,596 | +83.3% | 0.00% | – |
| Q4 2013 | $1,795,000 | – | 78,337 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |